
    
      The study is conducted in two phases, The phase I is the dose exploration phase, and the
      phase II is the dose expansion phase. The phase I clinical trial is to select an acceptable
      safe dose for the phase II clinical trial to further determine safety, pharmacokinetics and
      efficacy of this combination regimen in patients with specific tumor types.
    
  